Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 days ago

Opus Genetics, Inc.: BALYASNY ASSET MANAGEMENT L.P. amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Balyasny Asset Management L.P. amended its Schedule 13G filing on Opus Genetics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001172661-26-005045. The amendment signals a change in the hedge fund's position in the clinical-stage gene therapy developer, which focuses on inherited retinal diseases. Schedule 13G filings are required of investors holding passive stakes above 5% of a company's shares, so the update indicates Balyasny's holdings have shifted since its prior disclosure. The specific size and direction of the stake change were not detailed in the filing headline. Investors will watch for further 13G or 13D filings to gauge whether Balyasny's interest in Opus Genetics is increasing or being trimmed.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Balyasny Asset Management L.P., Opus Genetics, Inc.